DURHAM, N.C., April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright Annual Global Life Sciences Conference on Monday, April 9, 2018 at 10:15 a.m. CET at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.  Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.


Investor Relations:Michelle LaSpaluto(919) 972-7115 ir@chimerix.com or Will O'Connor Stern Investor Relations Will@sternir.com  212-362-1200

Media: Becky VonsiatskyW2O Group bvonsiatsky@w2ogroup.com  413-478-2003

Primary Logo